Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 19289741.
- Also identified by DOI 10.1212/01.wnl.0000344417.42972.54.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this essay, we draw attention to some recent downsides and surprises of multiple sclerosis (MS) therapeutics. These include experiences with recent head-to-head trials of interferon-beta and glatiramer acetate, dose escalation trials, frustrating efforts with progressive MS trials, failures of smart concepts and designer therapies, and harsh lessons from newly observed adverse reactions.
Medical subject headings
- Immunosuppressive Agents
- Interferon Type I
- Multiple Sclerosis
- Peptides